Peptidase stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
=== The Taghi organisation === Ridouan Taghi is a former Dutch-Moroccan drug trafficker and crime boss. He was specialised in forming criminal groups and coalitions that operated as international cocaine cartels. He is suspected of being behind the orchestration of several assassinations, attacks, and kidnappings in connection to the Mocro-War. Documents produced by the Drug Enforcement Administration (DEA) of the United States, and sent to the Dutch police, exposed what appeared to be a super drug cartel headed by Ridouan Taghi, alongside Raffaele Imperiale (Camorra's drugs and arms dealer), Daniel Kinahan (Irish reputed gang boss) and Edin Gačanin (Bosnian drug trafficker). The DEA estimated that around a third of all cocaine trafficking in Europe was done through his organisation, with a virtually monopoly on Peruvian cocaine. After the decryption of the telecommunication servers of Ennetcom by the Dutch and Canadian authorities, it also exposed a very close and personal friendship between Ridouan Taghi, and Chilean cartel boss Rico "El Rico" Eduardo Riquelme Vega, who was arrested in Santiago, Chile in 2017. Following the arrest of Benaouf A. in 2013, and the assassinations of two rival drug lords, Gwenette Martha and Samir Bouyakhrichan in 2014, Taghi was able to establish himself as one of the most powerful drug traffickers in Europe. The Dutch government also considered him to be "one of the most dangerous drug traffickers in Europe". Ridouan Taghi was able to keep a very low profile and run his operation unknowingly for many years.
=== Uncertainty in absolute isotope ratios === Because many isotopic reference materials are defined relative to one another using the δ notation, there are few constraints on the absolute isotopic ratios of reference materials. For dual-inlet and continuous flow mass spectrometry uncertainty in the raw isotopic ratio is acceptable because samples are often measured through multi-collection and then compared directly with standards, with data in the published literature reported relative to the primary reference materials. In this case the actual measurement is of an isotope ratio and is rapidly converted to a ratio or ratios so the absolute isotope ratio is only minimally important for attaining high-accuracy measurements. However, the uncertainty in the raw isotopic ratio of reference materials is problematic for applications that do not directly measure mass-resolved ion beams. Measurements of isotope ratios through laser spectroscopy or nuclear magnetic resonance are sensitive to the absolute abundance of isotopes and uncertainty in the absolute isotopic ratio of a standard can limit measurement accuracy. It is possible that these techniques will ultimately be used to refine the isotope ratios of reference materials.
Avenir Suisse, founded in 1999 by fifteen of the largest Swiss companies. It is supported by over 130 companies to date. DCAF, the Geneva Centre for the Democratic Control of Armed Forces, founded in 2000 to research security sector governance and reform. Gottlieb Duttweiler Institute (GDI), conceived by Migros-founder Gottlieb Duttweiler in 1946. Horasis, which hosts the annual Horasis Global Meeting Liberal Institute, founded in 1979.
The use of both "ambient" and non-Saccharomyces wild yeasts carries both potential benefits and risk. Some winemakers feel that the use of resident/indigenous yeast helps contribute to the unique expression of terroir in the wine. In wine regions such as Bordeaux, classified and highly regarded estates will often tout the quality of their resident "chateau" strains. To this extent, wineries will often take the leftover pomace and lees from winemaking and return them to the vineyard to be used as compost in order to encourage the sustained presence of favorable strains. But compared to inoculated yeast, these ambient yeasts hold the risk of having a more unpredictable fermentation. Not only could this unpredictability include the presence of off-flavors/aromas and higher volatile acidity but also the potential for a stuck fermentation if the indigenous yeast strains are not vigorous enough to fully convert all the sugars. It is virtually inevitable that non-Saccharomyces wild yeast will have a role in beginning the fermentation of virtually every wine but for the wineries that choose to allow these yeasts to continue fermenting versus minimizing their influence do so with the intent of enhancing complexity through bio-diversity. While these non-Saccharomyces ferment glucose and fructose into alcohol, they also have the potential to create other intermediates that could influence the aroma and flavor profile of the wine. Some of these intermediates could be positive, such as phenylethanol, which can impart a rose-like aroma.
{\displaystyle {\frac {\left({\sqrt {a}}-{\sqrt {b}}\right)^{2}+\left({\sqrt {b}}-{\sqrt {c}}\right)^{2}+\left({\sqrt {c}}-{\sqrt {a}}\right)^{2}}{\left({\sqrt {a}}+{\sqrt {b}}+{\sqrt {c}}\right)^{2}}}\leq {\frac {4}{9}}\left({\frac {R}{r}}-2\right).}
Sources: en.wikipedia.org
==== In adolescence ==== There has been a significant focus in past research on adulthood, in regards to well-being and development and although eudaimonia is not a new field of study, there has been little research done in the areas of adolescence and youth. Research that has been done on this age group had previously explored more negative aspects than well-being, such as problem and risk behaviours (i.e. drug and alcohol use). Researchers who conducted a study in 2013 recognized the absence of adolescents in eudaimonic research and the importance of this developmental stage. Adolescents rapidly face cognitive, social and physical changes, making them prime subjects to study for development and well-being. The eudaimonic identity theory was used in their research to examine the development of identity through self-discovery and self-realization. They emphasize the personal value found in discovering and appeasing one's "daimon" (daemon) through subjective experiences that develop eudaimonic happiness from aligning with one's true self. Researchers focused their studies on PYD (positive youth development) and the eudaimonic identity theory in the context of three developmental elements: self-defining activities, personal expressiveness and goal-directed behaviours. They determined that adolescents sample multiple self-defining activities; these activities aid in identity formation, as individuals choose activities that they believe represents who they are. These self-defining activities also help determine the adolescent's social environments.
This inhibition can lead to a depletion of dopamine and norepinepherine in the brain due to the lack of the precursor L-DOPA (L-3,4-dyhydroxyphenylalanine) which is synthesized by tyrosine hydroxylase. This drug is rarely used and can cause depression, but it is useful in treating pheochromocytoma and also resistant hypertension. Older examples of inhibitors mentioned in the literature include oudenone and aquayamycin.
== Plot == The Combine have opened an interdimensional portal in place of the destroyed Citadel, to summon reinforcements and defeat the Resistance. Outside City 17, Gordon Freeman and Alyx Vance escape the wreckage of a train they used to flee the city. They proceed to a transmission station, where they make contact with Dr. Isaac Kleiner and Dr. Eli Vance, who have arrived at the White Forest rocket facility. Kleiner and Eli learn that a copied Combine transmission Alyx is carrying may be able to close the portal. Gordon and Alyx reach an abandoned mine, where Alyx is critically wounded by a Combine Hunter. A vortigaunt leads them to an underground outpost, where Gordon is instructed to help gather larvae from an antlion colony to heal Alyx. After the larvae are gathered, vortigaunts begin to heal Alyx. With their abilities diverted, the G-Man can now connect to Gordon. He reveals that he rescued Alyx from Black Mesa during the Resonance Cascade, and that it is imperative she reaches White Forest. The G-Man instructs an unconscious Alyx to tell Eli to "prepare for unforeseen consequences". After Alyx recovers, they reunite with Eli, Kleiner and her pet robot, Dog, at White Forest and are introduced to Dr. Arne Magnusson. The scientists are preparing a rocket which they plan to use with the code to reverse the portal. After Gordon subdues a Combine attack on the facility, Alyx gives Kleiner a message recorded by Judith Mossman, which contains the location of the Borealis, a vanished Aperture Science research vessel.
The molecular mechanism behind the formation of these tumors is not well understood, likely due to their low prevalence. Currently, no mutations have been identified in association with thyrotroph adenomas. In the presence of other pituitary tumors, the thyrotropic cells are unaffected.
Sources: en.wikipedia.org
=== Proposed amalgamation === By early May 2026, several district and regional councils in Northland, Taranaki, the West Coast, Waikato, the Bay of Plenty, Wellington Wairarapa, Hawke's Bay and Southland Regions were discussing options to merge into unitary authorities as part of the Sixth National Government's policy of "simplifying" local government. On 5 May, the Local Government Minister Simon Watts and the RMA Reform Minister Chris Bishop issued local councils with a three-month timeframe to come up with amalgamation plans under the new "Head Start" approach. These amalgamation plans replaced the earlier proposed "combined territorial boards" and would be assessed by the newly-established Ministry for Cities, Environment, Regions and Transport (MCERT). The Government's 2026 amalgamation ultimatum received support from several local government leaders including Mayor of Nelson Nick Smith, Mayor of Southland Rob Scott, Mayor of Timaru Nigel Brown, Mayor of South Wairarapa Dame Fran Wilde, Mayor of Whangārei Ken Couper, Mayor of New Plymouth Max Brough, and Mayor of Invercargill Tom Campbell. By contrast, Mayor of Gore Ben Bell and Mayor of Rotorua Tania Tapsell expressed reservations about merger and the short time-frame. Meanwhile Mayor of Tasman Tim King preferred that the central government decide the local government model rather than delegating it to local councils.
American kestrels in Canada and the northern United States typically migrate south in the winter, some of them converging with resident kestrels of smaller size in Mexico, sometimes going as far as Central America and the Caribbean. Birds that breed south of about 35° north latitude are usually year-round residents. Migration also depends on local weather conditions. American Kestrels breeding at lower latitudes – below 48ºN to be precise – arrive earlier after warmer springs, whereas birds from higher latitudes return to their breeding grounds at the same time each year. These patterns suggest that short-distance migrants are better able to cope with climate change. Wintering kestrels' choice of habitat varies by sex. Females are found in open areas more often than males during the non-breeding season. A common explanation for this behavior is that the larger females who are bigger than the males arrive at the preferred habitat first and exclude males from their territory. The American kestrel is not long-lived, with a lifespan of <5 years for wild birds. The oldest banded wild bird was 11 years and 7 months, while captive kestrels can live up to 14–17 years. In a study, humans accounted for 43.2% of 1,355 reported deaths, which included direct killing and roadkills, while predation (including by larger birds of prey) accounted for 2.8%. This statistic is likely biased, however, as reported deaths are usually found near or in areas populated by humans.
The Bergmann degradation is a series of chemical reactions designed to remove a single amino acid from the carboxylic acid (C-terminal) end of a peptide. First demonstrated by Max Bergmann in 1934, it is a rarely used method for sequencing peptides. The later developed Edman degradation is an improvement upon the Bergmann degradation, instead cleaving the N-terminal amino acid of peptides to produce a hydantoin containing the desired amino acid. The Bergmann degradation follows the earlier work of Bergmann and his close colleague Leonidas Zervas, combining the organic azide degradation of the Curtius rearrangement with the Bergmann-Zervas carbobenzoxy method, which they designed to occur under relatively mild conditions so as to allow peptide sequencing. A single round of the Bergmann degradation yields an aldehyde containing the sought after amino acid residue and the remaining fragment of the original peptide in amide form.
==== Americas ==== Between 1963 and 1966, numerous scientific studies demonstrated the use of 99mTc as radiotracer or diagnostic tool. As a consequence the demand for 99mTc grew exponentially and by 1966, Brookhaven National Laboratory was unable to cope with the demand. Production and distribution of 99mTc generators were transferred to private companies. "TechneKow-CS generator", the first commercial 99mTc generator, was produced by Nuclear Consultants, Inc. (St. Louis, Missouri) and Union Carbide Nuclear Corporation (Tuxedo, New York). From 1967 to 1984, 99Mo was produced for Mallinckrodt Nuclear Company at the Missouri University Research Reactor (MURR). Union Carbide actively developed a process to produce and separate useful isotopes like 99Mo from mixed fission products that resulted from the irradiation of highly enriched uranium (HEU) targets in nuclear reactors developed from 1968 to 1972 at the Cintichem facility (formerly the Union Carbide Research Center built in the Sterling forest in Tuxedo, New York (41°14′6.88″N 74°12′50.78″W)). The Cintichem process originally used 93% highly enriched U-235 deposited as UO2 on the inside of a cylindrical target. At the end of the 1970s, 200,000 Ci (7.4×1015 Bq) of total fission product radiation were extracted weekly from 20 to 30 reactor bombarded HEU capsules, using the so-called "Cintichem [chemical isolation] process." The research facility with its 1961 5-MW pool-type research reactor was later sold to Hoffman-LaRoche and became Cintichem Inc. In 1980, Cintichem, Inc.
Afrezza, developed by Mannkind, was authorized by the FDA in June 2014 for use in adults with Type 1 and Type 2 diabetes, with a label restriction limiting its use only to those who also have asthma, active lung cancer, or chronic obstructive pulmonary disease (COPD). Rapid-acting inhaled insulin is a component of the drug-device combination solution that is used at the start of every meal. It employs technosphere technology, which appears to have a more practical delivery method and more dosing flexibility, and a new inhaled insulin formulation (2.5 m). A thumb-sized inhaler with improved dosage flexibility is used to deliver inhalable insulin. It includes powder-dissolved recombinant human insulin (fumaryl diketopiperazine). Technosphere insulin is quickly absorbed by the lung surface after inhalation. Within 12 hours of inhalation, both substances—insulin, and powder (fumaryl diketopiperazine)—are virtually eliminated from healthy people's lungs. In comparison to Exubera (8–9%), just 0.3% of inhaled insulin was still present in the lungs after 12 hours. However, since serum antibody levels have been reported to increase without substantial clinical changes, acute bronchospasm in asthmatic and COPD patients along with a significant reduction in Diffusing Lung Capacity for Carbon Monoxide, in comparison to subcutaneous insulin, have been reported with its usage, Afrezza was given FDA approval with a warning (Risk Evaluation and Mitigation Strategy).
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.